Silence Therapeutics Plc ADR (NASDAQ:SLN)’s traded shares stood at 0.72 million during the last session, with the company’s beta value hitting 1.05. At the close of trading, the stock’s price was $7.10, to imply an increase of 0.42% or $0.03 in intraday trading. The SLN share’s 52-week high remains $27.72, putting it -290.42% down since that peak but still an impressive 18.17% since price per share fell to its 52-week low of $5.81. The company has a valuation of $335.19M, with an average of 0.53 million shares in intraday trading volume over the past 10 days and average of 480.29K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Silence Therapeutics Plc ADR (SLN), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give SLN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Silence Therapeutics Plc ADR (NASDAQ:SLN) trade information
After registering a 0.42% upside in the last session, Silence Therapeutics Plc ADR (SLN) has traded red over the past five days. The 5-day price performance for the stock is 11.99%, and -4.83% over 30 days. With these gigs, the year-to-date price performance is -59.12%. Short interest in Silence Therapeutics Plc ADR (NASDAQ:SLN) saw shorts transact 0.35 million shares and set a 2.36 days time to cover.
The extremes give us $49 and $55 for target low and target high price respectively. As such, SLN has been trading -674.65% off suggested target high and -590.14% from its likely low.
Silence Therapeutics Plc ADR (SLN) estimates and forecasts
Looking at statistics comparing Silence Therapeutics Plc ADR share performance against respective industry, we note that the company has underperformed competitors. Silence Therapeutics Plc ADR (SLN) shares are -62.63% down over the last 6 months, with its year-to-date growth rate lower than industry average at -20.69% against 16.40%. The rating firms project that company’s revenue will shrink -18.23% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 3.73M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 3.05M.Earnings reports from the last fiscal year show that sales brought in 2.1M and 12.41M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 77.86% before dropping -75.42% in the following quarter.
SLN Dividends
Silence Therapeutics Plc ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Silence Therapeutics Plc ADR (NASDAQ:SLN)’s Major holders
Silence Therapeutics Plc ADR insiders hold 16.94% of total outstanding shares, with institutional holders owning 62.77% of the shares at 75.57% float percentage. In total, 62.77% institutions holds shares in the company, led by TCG CROSSOVER MANAGEMENT, LLC. As of 2024-06-30, the company held over 3.3 million shares (or 7.4962% of shares), all amounting to roughly $62.61 million.
The next major institution holding the largest number of shares is ARTAL GROUP S.A. with 2.78 million shares, or about 6.323% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $52.81 million.
